Candel Therapeutics (NASDAQ:CADL) Price Target Cut to $20.00 by Analysts at Citigroup

Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective lowered by Citigroup from $26.00 to $20.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price objective suggests a potential upside of 228.41% from the stock’s previous close.

A number of other research analysts have also recently issued reports on CADL. Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Thursday, October 15th. HC Wainwright decreased their target price on Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Friday. Canaccord Genuity Group dropped their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group assumed coverage on Candel Therapeutics in a research report on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective for the company. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.29.

Check Out Our Latest Stock Analysis on Candel Therapeutics

Candel Therapeutics Price Performance

CADL stock traded down $0.11 during trading on Monday, hitting $6.09. The company had a trading volume of 1,996,615 shares, compared to its average volume of 1,451,537. The firm has a market capitalization of $466.00 million, a price-to-earnings ratio of -4.06 and a beta of -0.27. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average of $9.75 and a 200 day moving average of $8.39. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $14.00.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. As a group, research analysts predict that Candel Therapeutics will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CADL. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Candel Therapeutics in the third quarter worth $41,000. Legal & General Group Plc purchased a new position in Candel Therapeutics in the 2nd quarter worth approximately $63,000. Cetera Investment Advisers purchased a new position in shares of Candel Therapeutics during the third quarter valued at approximately $124,000. Renaissance Technologies LLC purchased a new position in Candel Therapeutics in the first quarter worth about $63,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after acquiring an additional 2,301 shares during the period. 13.93% of the stock is owned by hedge funds and other institutional investors.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Analyst Recommendations for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.